Top Biotech Startups-2021
Pharma Tech Outlook
Home »BioTech Startup » Top Biotech Startups
Tempo Bioscience: A Transformative Approach to Drug Discovery and Development
line

Top 10 Biotech Startups - 2021

line

Despite being at the epicenter of the COVID-19 pandemic fallouts, the healthcare industry has been quick to bounce back up on its feet around the world. Helping the industry in this stride were cutting-edge biotech startups that were constantly making it easy for caregivers to aid, diagnose, and treat medical problems.

Presently, biotech startups are leveraging AI to automate a wide range of processes—from screening biomarkers as well as scraping through the scientific literature to discover novel products—and scale up the drug discovery process. They are also putting big data and analytics to use for tapping into the huge volume of healthcare data and driving innovation. It is allowing biopharma companies to recruit patients for clinical trials more effectively. At the same time, many biotech startups are even combining the powers of big data and AI to move to the next phase of deep learning for analyzing microbiomes, screening phenotypes, and developing rapid diagnostics.

In the face of such tremendous advancements, we have compiled this issue of Pharma Tech Outlook to help you in the task of finding the best biotech startup. In this edition, we have listed the most promising biotech startups to highlight those making significant contributions to the healthcare sector. Equipped with innovative technological capabilities, these companies are set to transform the landscape. This edition also blends thought leadership articles from subject matter experts and CXOs. We hope this issue of Pharma Tech Outlook helps you build the partnership you and your organization need to foster a care delivery model driven by robust and efficient technology.

We present to you Pharma Tech Outlook’s, “Top 10 BioTech Startups – 2021.”

    Top Biotech Startups

    AltrixBio
    Read full profile →
    AltrixBio is an innovative BioTech Startup that banks on this very idea while giving it a revolutionary spin! They aim to treat the “Treacherous Trifecta: Obesity, Diabetes, and Fatty Liver Disease” through an orally administered proprietary therapeutic, LuCI™ AJN 003, which provides a duodenal isolation of the proximal gut without entering the bloodstream. After initial results published in Nature Materials, the company has demonstrated preclinical enabling studies in chronic animal models, had a successful Pre-IND meeting for an expedited drug development pathway, and preparing for human studies in 2022 ... read full profile
    PhenoVista Biosciences
    Read full profile →
    PhenoVista Biosciences is a service provider of high-content, imaging-based, phenotypic assay development and screening services. It is a flexible and collaborative research partner that offers various engagement structures, assay types, and applications. PhenoVista is a one hundred percent service-based business that works with biopharma clients of all sizes, ranging from start-ups to established global entities. It provides assay development services that encompass various cell types and models, both 2D and 3D, human iPSC-derived neuronal health, mitochondrial structure and function, and many more ... read full profile
    Strategikon Pharma
    Read full profile →
    With its SaaS business platform—Clinical Maestro™, Strategikon Pharma helps biotech startups and biopharma organizations coalesce all the key processes for planning a clinical study. As an upshot of this integrated approach, the platform turns clinical trial budgeting, sourcing, and outsourcing management—into one seamless experience. Clinical Maestro, while bringing a new level of precision and speed to outsourced clinical trial operations, comes with a few groundbreaking characteristics. It provides benchmark costs for over 800 standardized tasks,timelines & billing rates across 70 roles and 80 countries to speed budget creation and give you confidence in your numbers ... read full profile
    Tempo Bioscience
    Read full profile →
    Tempo Bioscience develops human inducible pluripotent stem cells (iPSCs) that facilitate drug discovery and development, biobanking, and biomarker development programs. These cell models enable researchers to evaluate promising drug candidates during preclinical trials and pave the way for clinical development. The most significant advantage of using iPSC-based cell models is, unlike primary cells and immortalized cell lines, iPSCs from patients are genetically defined and manifest their disease phenotypes appropriately. Besides, along with iPSC-based cell models, the company also offers Phenotypic cell-based and target-based assay systems using Tempo Biosensors, which are intensiometric fluorescent reporters of LIVE-cell imaging and reporting of cell-based activities in real time ... read full profile
    Alzamend Neuro
    Alzamend Neuro™, Inc., (“Alzamend™)” is a Delaware corporation with its corporate headquarters in Tampa, Florida with nexus in California. The mission of Alzamend Neuro™ is to help the Alzheimer’s community by supporting the full product development life cycle of treatment and cures for Alzheimer’s Disease (“AD”) driven by the belief that strong support of research is the foundation for true innovation. The Company is providing hope through the commercialization of existing patented intellectual properties and know-how while simultaneously funding future treatments for other neurodegenerative diseases and psychiatric disorders, through advanced research and development
    ClearLight Biotechnologies
    ClearLight Biotechnologies (formerly ClearLight Diagnostics, LLC) was founded in 2015 by Karl Deisseroth MD, PhD, the inventor of CLARITY, Optogenetics, and STARmap technologies. It is an early stage company focused on developing automated instrumentation and associated reagents to simplify and expedite non-destructive 3D tissue analysis to facilitate preclinical and clinical research applications. The platform will enable an end-to-end solution for 3D analysis of preclinical and clinical models of disease
    Eikonoklastes Theraputics
    Eikonoklastes Therapeutics is a preclinical-stage biopharmaceutical company developing next-generation tissue factor (TF) immunotherapies. Eikonoklastes is advancing a new generation of tissue factor (TF) immunotherapies – therapeutics designed to target the cell surface receptor now known to be prevalent on key components of the tumor microenvironment. It has recently been discovered that certain pathological cells – but not healthy cells – including cancers with high unmet need and high mortality such as triple-negative breast cancer, ovarian cancer, metastatic melanoma, and a broad range of other solid tumors, express tissue factor on the surface of their cell membranes. Several other non-cancerous indications such as endometriosis also highly and selectively express tissue factor
    EQRx
    EQRx is committed to making innovative medicines at dramatically lower prices for the benefit of people and society. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. Headquartered in Cambridge, Massachusetts, the company is backed by GV, ARCH Venture Partners, Andreessen Horowitz, Casdin Capital, Section 32, Nextech, and Arboretum Ventures
    LevitasBio
    LevitasBio is advancing science and human health by providing researchers with a new and powerful method of cellular analysis. Magnetic levitation is the first truly novel approach to cellular analysis in 30 years. Extensive research has shown that cells of different types or states have unique physical signatures, levitating in predictable ways. Here’s how it works
    Nanotein Technologies
    Nanotein Technologies enables best-in-class cell therapies, by innovating the next generation of activation and expansion technologies. Using our novel platform technology, we at Nanotein, help overcome the CAR-T industry challenges by: (1) accelerating CAR-T expansion, (2) enhancing expansion to grow more cells per treatment, and (3) shifting the growth profile of CAR-T cultures to favor the expansion of the most long-lived and clinically effective CAR-T cell sub-populations. The uniquely tunable and flexible nature of our platform technology also allows us to easily modify our product. With the ability to make these simple changes we can grow CAR-T and T-cell cultures with new cell population profiles and growth curves